Search clinical trials for: beclomethasone/formoterol (100/6µg) pMDI

Total 219 results

Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclometasone/Formoterol Single Inhaler in Patients With Moderate to Severe Persistent Asthma

Asthma
Chiesi Farmaceutici S.p.A.

Completed

Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients (ADO pMDI)

Asthma

Poland
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD

Chronic Obstructive Pulmonary Disease

France
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD

Chronic Obstructive Pulmonary Disease

Hungary
Chiesi Farmaceutici S.p.A.

Completed

Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma. (FORTUNE)

Asthma

China
Chiesi Farmaceutici S.p.A.

Completed

A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler

Asthma

United Kingdom
Chiesi Farmaceutici S.p.A.

Completed

Triple in Asthma Dose Finding (Triskel)

Asthma

Bulgaria, Germany, Hungary, Italy, Poland, United Kingdom
Chiesi Farmaceutici S.p.A.

Withdrawn

Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children

Asthma in Children

Denmark
Adamis Pharmaceuticals Corporation

Withdrawn

Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma

Asthma
Chiesi Farmaceutici S.p.A.

Completed

Foster® pMDI (CHF 1535) Versus Symbicort® Turbohaler in COPD Patient (FORSYYN)

Chronic Obstructive Pulmonary Disease

China
Chiesi Farmaceutici S.p.A.

Completed

Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children

Childhood Asthma

Denmark
University Hospital, Antwerp
Chiesi Farmaceutici S.p.A.

Completed

Study to Assess the Effect of the NEXThaler® Device (DPI - Dry Powder Inhaler) on the Central and Peripheral Airway Dimensions in Asthmatic Patients

Asthma

Belgium
Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers

COPD

Belgium
Orion Corporation, Orion Pharma

Completed

Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing (EASYRELIEF)

Asthma

Finland
Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers

Asthma

Belgium
Chiesi Farmaceutici S.p.A.

Completed

An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects (BEAM)

Asthma

United States
Mundipharma Research Limited

Completed

A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy Volunteers

Asthma

United Kingdom
BlueWillow Biologics
Porton Biopharma Ltd.

Completed

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults (IN NE-rPA)

Anthrax

United States
Adamis Pharmaceuticals Corporation

Withdrawn

Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma

Asthma
Chiesi Farmaceutici S.p.A.

Completed

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment. (TRIPLE10)

Chronic Obstructive Pulmonary Disease (COPD)

Poland
Chiesi Farmaceutici S.p.A.

Completed

Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients (TRIPLE 4)

COPD

Poland
Chiesi SAS
Kappa Santé

Recruiting

Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT Study (TriNEXT)

COPD

France
AstraZeneca

Recruiting

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS) (LOGOS)

Asthma

United States, China, Czechia, Germany, South Africa, United Kingdom, Mexico, Turkey, Colombia, Russian Federation, Brazil, Israel, Greece, Portugal, Austria, Costa Rica, Saudi Arabia, Slovakia, Sweden, Puerto Rico
AstraZeneca

Recruiting

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS) (KALOS)

Asthma

United States, Canada, Denmark, Hungary, New Zealand, Poland, Spain, Korea, Republic of, Philippines, Italy, Argentina, Bulgaria, India, Japan, Vietnam, Taiwan, Thailand, Peru, Chile, Puerto Rico, Belgium, Australia, Netherlands, Romania
Chiesi Farmaceutici S.p.A.
SGS S.A.

Recruiting

Clinical Study to Evaluate the Safety, Tolerability and the Concentration of the BDP (Beclomethasone Dipropionate), Active Metabolite of BDP, FF( Formoterol Fumarate) and GB (Glycopyrronium Bromide), After Inhalation of CHF 5993 at Two Different Doses and QVAR®

Asthma

Belgium
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclomethasone Dipropionate/Formoterol Single Inhaler in Patients With Mild to Moderate Persistent Asthma

Asthma
Chiesi Farmaceutici S.p.A.

Completed

Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients

Chronic Obstructive Pulmonary Disease | Asthma
Mundipharma Research Limited

Completed

Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.

Mild Persistent Asthma

Denmark
Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old (PAED1)

Asthma

Denmark
AstraZeneca
Parexel

Completed

A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers

Study is Being Conducted in Healthy Volunteers

United Kingdom
Research in Real-Life Ltd
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared With ICS/LABA Combination Therapy (QvarvsCombo)

Asthma

United Kingdom
Organon and Co

Completed

A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241) (SPIRO)

Asthma
Chiesi Farmaceutici S.p.A.

Completed

Clinical Pharmacology of 35/4 NEXThaler® in Children 5-11 Years Old

Asthma

Denmark
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults

Pharmacokinetics

United States
UPECLIN HC FM Botucatu Unesp
Chiesi Farmaceutici S.p.A.

Active, not recruiting

Efficacy of Inhaled Therapies in the Treatment of Acute Symptoms Associated With COVID-19 (TRIVID)

Covid19

Brazil
Chiesi Farmaceutici S.p.A.

Completed

Efficacy Study of the Product "CHF 1535" Versus Beclomethasone (BDP) and Free Combo in Asthmatic Children (PAED2/FRESH)

Asthma

Spain, France, Romania, Bulgaria, Germany, Hungary, Italy, Poland, Russian Federation, Slovakia, Ukraine
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

Chronic Obstructive Pulmonary Disease

United States, Germany, United Kingdom, China, Taiwan, Korea, Republic of, Japan, Czechia, Hungary, Poland, Russian Federation
Zhujiang Hospital

Unknown

Small Airways Evaluation and Treatment

Pulmonary Disease，Chronic Obstructive;

China
SkyePharma AG

Completed

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma

Asthma

United States, Canada
Chiesi Farmaceutici S.p.A.

Withdrawn

TRIMBOW® and RELVAR® on Lung Stiffness Reduction Assessed Through Forced Oscillation Technique in Patients With COPD

COPD
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

Asthma

United States
The First Affiliated Hospital of Guangzhou Medical...
Guangdong Provincial Hospital of Traditional Chinese Medicine; Tongji Hospital and other collaborators

Not yet recruiting

Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough. (CC-ICS)

Cough

China
Hull University Teaching Hospitals NHS Trust
Chiesi Farmaceutici S.p.A.

Completed

Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United Kingdom
SkyePharma AG

Completed

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

Asthma

United States, Canada
Chiesi Farmaceutici S.p.A.

Active, not recruiting

A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared to CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid (FORCE2)

Asthma

United States
Organon and Co
Novartis

Completed

Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)

Asthma
Chiesi Farmaceutici S.p.A.

Completed

Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)

Bronchial Asthma

Austria, Poland, Ukraine
Research in Real-Life Ltd
Aerocrine AB

Completed

The Evaluation of FeNO for Predicting Response to ICS in Subjects With Non-specific Respiratory Symptoms (NSRS)

Asthma

United Kingdom
AstraZeneca

Completed

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients

Chronic Obstructive Pulmonary Disease

United States, Czech Republic, Poland, South Africa, Netherlands
Humanis Saglık Anonim Sirketi

Completed

To Investigate Drug-drug Interaction and Relative Bioavailability Between the FDC AzelastineHCL/Beclomethasone Dipropionate Nasal Spray, & Beclomethasone Dipropionate Nasal Spray in the Test Vehicle, and RinoClenil® Nasal Spray

Seasonal Allergic Rhinitis

Jordan

3

Subscribe